

SPONSOR AGREEMENT

This Sponsor Agreement (“**Agreement**”) is entered into the date of the last signature (“**Effective Date**”) by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark (“**Novartis**”) and **Danmarks Bløderforening** an organization incorporated under the laws of Denmark, (“**Sponsor Recipient**”). Novartis and Sponsor Recipient may hereinafter be referred to individually as a “**Party**” and collectively as the “**Parties**”.

WHEREAS, Sponsor Recipient has specifically requested Novartis’ financial contribution to support the Sponsor Activity (as defined in Exhibit A), through a Sponsor Request Letter, which is attached hereto as Exhibit B.

WHEREAS, in accordance with the Sponsor Request Letter mentioned above, Novartis wishes to support the Sponsor Activity with the Sponsor Amount (as defined in Exhibit A).

WHEREAS, Novartis will receive a tangible benefit in connection with the Sponsor (as defined in Exhibit A); and

WHEREAS Sponsor Recipient accepts the Sponsor Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. SPONSOR BY NOVARTIS

1.1 **Sponsor.** Novartis will provide the Sponsor Amount as set forth in Exhibit A solely to support Sponsor Recipient in performing the Sponsor Activity as set forth in Exhibit A.

1.2 **Tangible benefit.** Novartis will receive a tangible benefit as set forth in Exhibit A.

1.3 **Statement of Purpose. The Sponsor Activity is for “Update of information material for Immune Trombocytopeni”**

1.4 **Novartis Responsibility.** Sponsor Recipient agrees that Novartis’ responsibility is solely to provide the Sponsor Amount and to receive the tangible benefit. Novartis will not be liable to Sponsor Recipient or to any other person for the Sponsor Activity or the use of the Sponsor Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Sponsor Recipient to return the Sponsor Amount and take other corrective action if Sponsor Recipient breaches this Agreement.

2. OBLIGATIONS OF SPONSOR RECIPIENT

2.1 **Use of Sponsor Amount.**



- (a) Sponsor Recipient shall use the Sponsor Amount solely for the Sponsor Activity and shall not use the Sponsor Amount for any activity that is inconsistent with, or prohibited by any law, rule, or regulation. The Sponsor Recipient undertakes to independently contact Novartis in the event any part of the Sponsor Amount has not been used for the Sponsor Activity so that such amount can be refunded to Novartis without undue delay.
- (b) Sponsor Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules, and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Sponsor Activity. Sponsor Recipient warrants that the Sponsor Activity is compliant with all such requirements.
- (c) Sponsor Recipient is solely responsible because the Sponsor Amount is disbursed, recorded, and accounted and for all contractual and other relationships with third parties relating to the Sponsor Activity and the use of the Sponsor Amount. Any claims for payment from third parties involved in the Sponsor Activity are the sole responsibility of Sponsor Recipient and Novartis will not fund any additional amounts for the Sponsor Activity.

2.2 Objectivity and Balance.

- (a) The Sponsor Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Sponsor Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading, or deceptive and in compliance with all applicable laws, rules, and regulations. Where appropriate, the Sponsor Activity will include a discussion of multiple treatment options and will not focus on a single product.
- (c) Sponsor Recipient will ensure that any titles or overview information relating to the Sponsor Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Sponsor Recipient is responsible for selection of presenters, moderators, and collaborators for the Sponsor Activity. Novartis will not control the planning, content, speaker selection or execution of any Sponsor Activity. If Novartis suggests presenters, moderators or collaborators, Sponsor Recipient will record the role of Novartis in suggesting, seek other sources and make a final selection based on balance and independence.

2.3 Disclosure of Financial Relationships.

- (a) Sponsor Recipient will: (i) disclose, to all audiences and in all publications relating to the Sponsor Activity, that Novartis has provided a Sponsor to support the Sponsor Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Sponsor Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Sponsor Recipient which a reasonable and ethical person would expect to be disclosed.



- (b) Novartis may disclose publicly the financial and non-financial support provided to Sponsor Recipient, including, without limitation, the Sponsor Recipient's identity, the Sponsor Amount, and purpose of the support.

2.4 **Ancillary Activities.**

- (a) If the Sponsor Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Sponsor Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Sponsor Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Sponsor Activity is at the sole discretion of Sponsor Recipient. Meals and/or receptions, if any, will be modest and conducive to the Sponsor Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) **Reconciliation of Expenses.** At the conclusion of the Sponsor Activity, Sponsor Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Sponsor Amount not incurred in the implementation of the Sponsor Activity. In addition, Sponsor Recipient will retain appropriate records of the Sponsor Activity and the use of the Sponsor Amount and will provide evidence (as further specified in Exhibit A) to Novartis to document that the Sponsor Amount has been used in accordance with this Agreement.

3. **GENERAL**

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.



IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.

Novartis Healthcare A/S

Danmarks Bløderforening

Signature: _____
DocuSigned by:
Trine Lassen
05B83969DBDF479...

Signature: _____
DocuSigned by:
Karen Binger Holm
62431D059250429...

Name: Trine Lassen

Name: Karen Binger Holm

Title: Portfolio Manager, Essential Medicine

Title: Sekretariatsleder

Date: _____ 27-Nov-23 | 12:26:28 PM GMT

Date: _____ 27-nov-23 | 8:14:45 AM PST

Signature: _____
DocuSigned by:
Mads Thomsen
1797D74A2445448...

Name: Mads Thomsen

Title: Business Excellence & Execution
Director

Date: _____ 27-Nov-23 | 1:50:11 PM GMT



EXHIBIT A

SPONSOR AMOUNT AND ACTIVITY

Sponsor Amount: **36,323 DKK**

Sponsor Activity:

Update of written information material to patients and relatives, regarding Immune Thrombocytopenia (ITP). The material will be uploaded to the society's homepage and sent out to hospitals with hematological departments.

Tangible Benefit:

Novartis Healthcare will be mentioned in the information material.

Evidence must be provided to Novartis upon completion of the Sponsor Activity.

Payment:

The Sponsor amount is payable against the corresponding invoice within sixty (30) days of its receipt and at the end of a calendar month.

EXHIBIT B**SPONSOR REQUEST LETTER**

<p>Novartis Healthcare A/S Edvard Thomsens Vej 14, 3 sal 2300 København S</p> <p>Att.: Susanne Strauss Rasmussen susanne.strauss@novartis.com</p>	<p>Danmarks Bløderforening Blekinge Boulevard 2 2630 Taastrup Tlf. 3314 5605 www.bloderforeningen.dk</p> 
<p>Den 13. november 2023</p>	
<p>Ansøgning om støtte til opdatering af informationsmateriale om Immun Trombocytopeni (ITP)</p>	
<p>Danmarks Bløderforening vil med denne ansøgning søge Novartis Healthcare A/S om støtte på 36.323 kr. til opdatering af skriftligt informationsmateriale om ITP målrettet patienter og pårørende.</p>	
<p>ITP rammer årligt 3-4 pr. 100.000 voksne og mellem 40-50 børn. Viden om sygdommen er begrænset, og i Danmarks Bløderforening oplever vi løbende efterspørgsel på information om sygdommen og behandlingsmuligheder fra både patienter og pårørende og sundhedsprofessionelle.</p>	
<p>Der er sket meget på behandlingsområdet de senere år. Formålet er derfor at sikre opdateret information i lægmandssprog om sygdommen og forskellige behandlingsmuligheder, og gennem personlige historier at beskrive livet med ITP anno 2023.</p>	
<p>Den nuværende pjece er fra 2014 og er tilgængelig online: https://www.bloderforeningen.dk/media/ojvfhshu/itp-h%C3%A5ndbog_k3_ops.pdf.</p> <p>Den nuværende pjece indeholder forældet information og også produktnavne. Det vil vi i den nye version ændre, således at det alene er virkningstoffer, der fremgår. Foreningen samarbejder med overlæge Henrik Frederiksen, Hæmatologisk Afdeling, Odense Universitetshospital, om kvalitetssikring af det faglige indhold i teksten.</p>	
<p>Teksten vil blive formidlet i pjeceform, som kan downloades fra foreningens hjemmeside. Pjecen vil også blive trykt i et mindre fysisk oplag, da vi oplever efterspørgsel både blandt medlemmer og sundhedsprofessionelle på fysisk skriftligt materiale om ITP og livet med sygdommen, som det fremgår af nedenstående citat.</p>	
<p><i>"Hej, Jeg er sygeplejerske på blodsygdomme, AUH Skejby. Vi har tidligere fået pjecer vedr. ITP fra jer, og ønsker os en ny opdateret version til udlevering til vores patienter. Sidste er lavet i 2014 og er åbenbart udgået for bestilling. Mvh XX" (2023)</i></p>	
<p>I 2020-2022 er i gennemsnit udsendt 50 pjecer om året. Teksten vil også danne udgangspunkt for opdatering af information på foreningens hjemmeside: https://www.bloderforeningen.dk/viden-om/itp/</p>	
<p><small>CVR: 11 80 29 90 SE nr.: 11 80 29 90 Sydbank, Reg. nr.: 7040, Konto nr.: 1106847</small></p>	

Danmarks Bløderforening
Blekinge Boulevard 2
2630 Taastrup
Tlf. 3314 5505
www.bløderforeningen.dk



Den opdaterede pjøce udsendes til hospitaler med hæmatologiske basisfunktioner, hæmatologiske afdelinger og børneafdelinger.

Der søges om støtte på 36.323 kr. Det samlede budget er 120.641 kr., heraf egenfinansiering 11.671 kr. Foreningen søger om støtte blandt flere firmaer med produkter i markedet. Det vil fremgå af materialet, hvilke firmaer, der har muliggjort pjøcens udgivelse. Se vedlagte budget og tidsplan.

Enhver støtte modtages med tak!

Skulle der være spørgsmål til denne ansøgning, står jeg naturligvis til rådighed.

Venlig hilsen

Karen Binger Holm
Sekretariatsleder

BUDGET**BUDGET**

Opdatering af informationsmateriale om ITP

Udgifter	Samlede udgifter i DKK	Egenfinansiering	Søges	Noter
Eksternt layout og print Grafisk opsætning Korrekturlæsning 2-3 gange 500 stk., 21x21 cm. i farver Forsendelse til sekretariat	kr. 23.125		kr. 23.125	A
Lægefaglig kvalitetssikring Kvalificering af pjecens indhold (honorar)	kr. 2.500	kr. 2.500		B
Patientportrætter Bidrag til pjecens indhold (frivillig tid)	kr. 1.800	kr. 1.800		C
Tekstproduktion Tekstproduktion Interview med patienter Koordination med læger og patienter, som bidrager Tilpasning af tekst og cases til web Lancering	kr. 84.345		kr. 84.345	D
Transport Transport i forbindelse med tre interview af patienter i deres hjem.	kr. 1.500		kr. 1.500	E
Forsendelse	kr. 938	kr. 938		F
Projektledelse og administration	kr. 6.435	kr. 6.435		G
Total	DKK 120.641	kr. 11.671	kr. 108.970	

Noter:

A) Baseret på tilbud fra bureauet Synergi, 261023

B) Overlæge fra højtspecialiseret hæmofili-center kvalificerer pjecens indhold. Der gives et honorar på 2.500 kr. svarende til 5 timers arbejde af 500 kr.

C) Tre patienter bidrager med deres egen historie. Estimeret tidsforbrug: 3 timer pr. person, 200 kr./time

D) DBF kommunikationsmedarbejder, inkl. pension, Magistrene, overenskomst for ansatte i staten + arbejdsplads

E) Den estimerede transportudgift pr. patientbesøg er 500 kr.

F) Udsendelse, inkl. bølgeafdelinger: <https://www.hematology.dk/index.php/dhs/afdelinger>

G) Projektledelse og administration

TIDSPLAN 2024	Marts	April	Maj
Tekstproduktion	x	x	
Patienthistorier	x		
Faglig kvalificering		x	
Layout og print			x
Opdatering af website			x
Udsendelse og lancering			x

KBH/101123